肝性心肌病研究进展(3)
[11]Mocarzel L1， Lanzieri P1， Nascimento J，et al.Hepatorenal syndrome with cirrhotic cardiomyopathy： case report and literature review[J].Case Reports Hepatol，2015(22)：1155.
[12]Sampaio F， Lamata P，Bettencourt N，et al Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonancereveals impaired contractile reserve in patients with cirrhotic cardiomyopathy[J].J Cardiovasc Magn Reson，2015，17(1)：61.
[13]AchécarL， González-TallónA， MesoneroF，et al. Cirrhotic cardiomyopathy manifested by left ventricle diastolic dysfunction is a risk factor in the development of hepatorenal syndrome and lower survival[J]. Journal of Hepatology，2011，54 SUPPL. 1 (S50-S51)
[14]Somani PO，Contractor Q，Chaurasia AS，et al Diastolic dysfunction characterizes cirrhotic cardiomyopathy[J].Indian Heart J，2014，66(6)：649-655.
[15]Karagiannakis DS1， Papatheodoridis G， Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy[J].Dig Dis Sci，2015，60(5)：1141-1151.
[16]Wiese S，Hove JD，Bendtsen F，et al.Cirrhotic cardiomyopathy： pathogenesis and clinical relevance[J].Nat Rev Gastroenterol Hepatol，2014，11(3)：177-186.
[17]Liu L ，Liu H，Nam，et al.Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats[J].Dig Liver Dis，2012，44(12)：1012-1017.
编辑/蔡睿琳, 百拇医药(席东焱 马桂凤)
[12]Sampaio F， Lamata P，Bettencourt N，et al Assessment of cardiovascular physiology using dobutamine stress cardiovascular magnetic resonancereveals impaired contractile reserve in patients with cirrhotic cardiomyopathy[J].J Cardiovasc Magn Reson，2015，17(1)：61.
[13]AchécarL， González-TallónA， MesoneroF，et al. Cirrhotic cardiomyopathy manifested by left ventricle diastolic dysfunction is a risk factor in the development of hepatorenal syndrome and lower survival[J]. Journal of Hepatology，2011，54 SUPPL. 1 (S50-S51)
[14]Somani PO，Contractor Q，Chaurasia AS，et al Diastolic dysfunction characterizes cirrhotic cardiomyopathy[J].Indian Heart J，2014，66(6)：649-655.
[15]Karagiannakis DS1， Papatheodoridis G， Vlachogiannakos J. Recent advances in cirrhotic cardiomyopathy[J].Dig Dis Sci，2015，60(5)：1141-1151.
[16]Wiese S，Hove JD，Bendtsen F，et al.Cirrhotic cardiomyopathy： pathogenesis and clinical relevance[J].Nat Rev Gastroenterol Hepatol，2014，11(3)：177-186.
[17]Liu L ，Liu H，Nam，et al.Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats[J].Dig Liver Dis，2012，44(12)：1012-1017.
编辑/蔡睿琳, 百拇医药(席东焱 马桂凤)